Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Oklahoma Medical Research Foundation currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners, showing some variety in the prosecution staff assigned to the portfolio. Nelson B Moseley II is the busiest examiner for the company, overseeing 1 pending office action. The portfolio also spans 2 distinct art units.
For a practitioner, the distribution of actions across multiple examiners suggests that the portfolio is not dependent on a single individual's perspective. The presence of 2 distinct art units indicates that the foundation is engaging with different specialized groups within the patent office. This can be beneficial for diversifying risk, as a negative trend in one art unit may not affect the entire portfolio. However, it also requires managing different examination styles and timelines.
The focus on the Biotechnology & Pharmaceuticals technology area remains a core component of the foundation's intellectual property strategy. With 3 pending office actions, the foundation must coordinate its responses to ensure consistency across different examiners. Practitioners should monitor the specific tendencies of each assigned examiner to optimize the chances of allowance across these varied prosecution paths. This multi-examiner approach requires a robust tracking system to maintain a unified legal position.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSELEY II, NELSON B | 1 | 68.0% | +41.5% |
| KONOPKA, CATHERINE ANNE | 1 | 58.1% | +65.0% |
| COUNTS, GARY W | 1 | 58.9% | +29.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18016384 | METHOD FOR DETERMINING WHETHER A SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENT IS UNDERGOING A PRE-FLARE EVENT | COUNTS, GARY W | 5d |
| 18411242 | COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS USING A CD14 INHIBITOR | MOSELEY II, NELSON B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18016384 | METHOD FOR DETERMINING WHETHER A SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENT IS UNDERGOING A PRE-FLARE EVENT | COUNTS, GARY W | 5d |
| 18411242 | COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS USING A CD14 INHIBITOR | MOSELEY II, NELSON B | — |
| 18506519 | PROX1 PREVENTS MYXOMATOUS VALVE DISEASE BY INHIBITING PDGF-B SIGNALING | KONOPKA, CATHERINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18411242 | COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS USING A CD14 INHIBITOR | MOSELEY II, NELSON B | — | §103§112 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18506519 | PROX1 PREVENTS MYXOMATOUS VALVE DISEASE BY INHIBITING PDGF-B SIGNALING | KONOPKA, CATHERINE ANNE | 1635 | §112 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18016384 | METHOD FOR DETERMINING WHETHER A SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENT IS UNDERGOING A PRE-FLARE EVENT | COUNTS, GARY W | 1678 | §101§103 | Final Rejection | 5d | Pending | Jan 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial